Nissay Asset Management Corp Japan ADV Has $1.61 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Nissay Asset Management Corp Japan ADV cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 47.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,077 shares of the company's stock after selling 35,678 shares during the quarter. Nissay Asset Management Corp Japan ADV's holdings in Moderna were worth $1,608,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Moderna in the fourth quarter valued at $163,833,000. FMR LLC lifted its stake in Moderna by 7.4% in the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Pictet Asset Management Holding SA grew its position in shares of Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after acquiring an additional 1,113,455 shares during the period. Invesco Ltd. grew its position in shares of Moderna by 24.3% in the 4th quarter. Invesco Ltd. now owns 5,006,462 shares of the company's stock valued at $208,169,000 after acquiring an additional 979,858 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Moderna by 225.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company's stock worth $42,027,000 after purchasing an additional 700,458 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and cut their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Barclays dropped their price objective on Moderna from $45.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley reduced their target price on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. UBS Group dropped their price target on Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, JPMorgan Chase & Co. cut their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating for the company in a report on Thursday. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $53.58.

Moderna Stock Performance

Shares of NASDAQ MRNA traded down $0.95 during midday trading on Friday, reaching $25.77. The company's stock had a trading volume of 3,043,511 shares, compared to its average volume of 7,974,375. The company has a market cap of $9.97 billion, a P/E ratio of -2.79 and a beta of 1.99. The business's 50 day moving average price is $27.23 and its two-hundred day moving average price is $34.81. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. The firm had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. The company's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($3.07) EPS. Sell-side analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.